托法替布治疗老年人中重度类风湿性 关节炎疗效及安全性评价

Evaluation of Efficacy and Safety of Tofacitinib in the Treatment of Elderly Patients with Moderate and Severe Rheumatoid Arthritis

摘要:

〔摘 要〕 目的：研究老年中重度类风湿性关节炎患者使用托法替布的治疗效果以及临床用药的安全性。 方法：选择郑州大学附属郑州市中心医院 2020 年 1 月至 2021 年 1 月接诊的 100 例老年中重度类风湿性关节炎患者，按照患 者临床入院时间，将患者进行编号，其中奇数组为观察组，偶数组为对照组，各 50 例。对照组患者进行常规治疗， 观察组患者加用托法替布治疗，比较两组患者治疗效果、治疗前后的外周血类风湿因子（RF）、红细胞沉降率（ESR）、 C 反应蛋白（CRP）情况以及用药治疗的不良反应。 结果：观察组患者总有效率为 98.00 %，高于对照组的 80.00 %， 差异具有统计学意义（P ＜ 0.05）；观察组患者治疗后的外周血 RF、ESR、CRP 水平均明显低于对照组，差异具有 统计学意义（P ＜ 0.05）；观察组患者的不良反应发生率低于对照组，差异具有统计学意义（P ＜ 0.05）。 结论：在 常规治疗的基础上加用托法替布治疗，能够提高临床治疗效果，提高用药安全性，改善重度类风湿性关节炎情况，减 少不良反应。

Abstract:

〔Abstract〕 Objective To investigate the efficacy and safety of tofacitinib in the treatment of elderly patients with moderate to severe rheumatoid arthritis. Methods A total of 100 elderly patients with moderate to severe rheumatoid arthritis admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University from January 2020 to January 2021 were selected. According to the time of clinical admission, the patients were numbered. The odd-number group was the observation group, and the even-number group was the control group, with 50 cases in each group. The patients in the control group were treated with routine treatment, and the patients in the observation group were treated with tofacitinib. The therapeutic effect, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) before and after treatment, and adverse reactions of drug treatment were compared between the two groups. Results The total effective rate of the observation group was 98.00 %, higher than 80.00 % of the control group, and the difference was statistically significant (P < 0.05). After treatment, the levels of RF, ESR and CRP the observation group were significantly lower than those of the control group, and the differences were statistically significant (P < 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion On the basis of conventional treatment, tofacitinib can improve the clinical treatment effect, improve the safety of medication, improve the condition of severe rheumatoid arthritis, and reduce adverse reactions.